Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for Parkinson's disease from cell-to-cell in the brain.

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that damage brain ...

The PADOVA trial of alpha-synuclein-targeting antibody prasinezumab wasn't able to show a statistically significant extension in the time to motor progression in patients with early-stage ...

The assay for a particular abnormal form of the protein alpha-synuclein – known as αSyn-SAA – could also be used to diagnose people with Parkinson’s more quickly, help identify the best ...

The major mechanism behind Parkinson’s disease is well established – a toxic form of a protein called alpha-synuclein that accumulates inside neurons in clusters, eventually driving cell death ...

A drug that targets a build-up of proteins linked to Parkinson’s disease could slow the progression of motor symptoms in people with advanced forms of the condition. Although this shows promise ...

Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...

Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...

A drug that targets a build-up of proteins linked to Parkinson’s disease could slow the progression of motor symptoms in people with advanced forms of the condition. Although this shows promise ...